TY - JOUR
T1 - Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
AU - ATLAS Collaboration
AU - Ismail, Zahinoor
AU - Black, Sandra E.
AU - Camicioli, Richard
AU - Chertkow, Howard
AU - Herrmann, Nathan
AU - Laforce, Robert
AU - Montero-Odasso, Manuel
AU - Rockwood, Kenneth
AU - Rosa-Neto, Pedro
AU - Seitz, Dallas
AU - Sivananthan, Saskia
AU - Smith, Eric E.
AU - Soucy, Jean Paul
AU - Vedel, Isabelle
AU - Gauthier, Serge
AU - Gauthier, Serge
AU - Menard, Marie Chantal
AU - Lacombe, Guy
AU - Chayer, Celine
AU - Smith, Eric
AU - Black, Sandra
AU - Hachinski, Vladimir
AU - Hogan, David
AU - Lanctot, Krista
AU - Swartz, Rick
AU - Field, Thalia
AU - Barber, Phil
AU - Sharma, Mike
AU - Ganesh, Aravind
AU - Lindsay, Patrice
AU - Ismail, Zahinoor
AU - Laforce, Robert
AU - Smith, Eric
AU - Hsiung, Robin
AU - Bruneau, Marie Andree
AU - Fischer, Corinne
AU - Ducharme, Simon
AU - Tang-Wai, David
AU - Kumar, Sanjeev
AU - Burhan, Amer
AU - Herrmann, Nathan
AU - Shulman, Ken
AU - Massoud, Fadi
AU - Lee, Linda
AU - Soucy, Jean Paul
AU - Brisson, Melanie
AU - Brodeur, Catherine
AU - Theou, Olga
AU - Andrew, Melissa
AU - Theou, Olga
N1 - Funding Information:
The CCCDTD5 meeting was supported financially by the Canadian Consortium on Neurodegeneration in Aging, the , the . Réseau des cliniques mémoire du Québec Réseau Québecois de Recherche sur le Vieillissement
Publisher Copyright:
© 2020 the Alzheimer's Association
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence-based dementia guidelines for Canadian clinicians and researchers. We present the results of the 5th CCCDTD, which convened in October 2019, to address topics chosen by the steering committee to reflect advances in the field, and build on previous guidelines. Topics included: (1) utility of the National Institute on Aging research framework for clinical Alzheimer's disease (AD) diagnosis; (2) updating diagnostic criteria for vascular cognitive impairment, and its management; (3) dementia case finding and detection; (4) neuroimaging and fluid biomarkers in diagnosis; (5) use of non-cognitive markers of dementia for better dementia detection; (6) risk reduction/prevention; (7) psychosocial and non-pharmacological interventions; and (8) deprescription of medications used to treat dementia. We hope the guidelines are useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to dementia.
AB - Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence-based dementia guidelines for Canadian clinicians and researchers. We present the results of the 5th CCCDTD, which convened in October 2019, to address topics chosen by the steering committee to reflect advances in the field, and build on previous guidelines. Topics included: (1) utility of the National Institute on Aging research framework for clinical Alzheimer's disease (AD) diagnosis; (2) updating diagnostic criteria for vascular cognitive impairment, and its management; (3) dementia case finding and detection; (4) neuroimaging and fluid biomarkers in diagnosis; (5) use of non-cognitive markers of dementia for better dementia detection; (6) risk reduction/prevention; (7) psychosocial and non-pharmacological interventions; and (8) deprescription of medications used to treat dementia. We hope the guidelines are useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to dementia.
UR - http://www.scopus.com/inward/record.url?scp=85088587187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088587187&partnerID=8YFLogxK
U2 - 10.1002/alz.12105
DO - 10.1002/alz.12105
M3 - Article
C2 - 32725777
AN - SCOPUS:85088587187
SN - 1552-5260
VL - 16
SP - 1182
EP - 1195
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 8
ER -
